Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER) User HealthEconBot, in the Health Economics Journal Articles subreddit, 20 Apr 2018